ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

daratumumab

Also written as “Daratumumab”, “Daratumumab SC” and “Daratumumab IV”.

Its studies are mostly in Multiple Myeloma · Amyloidosis · Precursor Cell Lymphoblastic Leukemia-Lymphoma · Myelodysplastic Syndromes · Lymphoma, Mantle-Cell, led by 4 companies.

Drug pageDaratumumab: every studyAll 219 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Nov 29, 201833 company-led studies, 6 open or runningNext primary completion: Mar 8, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Johnson & Johnson284 open or runningphase 4since Nov 29, 2018Dec 14, 2007Jan 31, 2029phase 3 · NCT05438043
Bristol-Myers Squibbits history only31 open or runningphase 3since Aug 16, 2018May 12, 2016none ahead
Amgenits history only10 open or runningphase 3since May 9, 2017May 9, 2017none ahead
Celltrionits history only11 open or runningphase 3since Apr 29, 2025Apr 29, 2025Mar 8, 2027phase 3 · NCT06952478

Also a collaborator on its studies: Karyopharm Therapeutics.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Johnson & Johnson only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 12 studies since Dec 14, 2007.

  1. Oct 6, 20162 phase 2 studiesNCT02927925, NCT02951819
  2. Jan 4, 2017Phase 2 study in Myelodysplastic SyndromesNCT03011034 · 34 enrolled · United States, Belgium, Italy and more
  3. Jun 27, 2017Phase 3 study in AmyloidosisNCT03201965 · 416 enrolled · United States, Australia, Belgium and more
  4. Jul 13, 20172 phase 3 studies in Multiple MyelomaNCT03217812, NCT03234972
  5. Sep 7, 2017Phase 3 study in Multiple MyelomaNCT03277105 · 522 enrolled · United States, Australia, Brazil and more
  6. Dec 20, 2017Phase 2 study in Precursor Cell Lymphoblastic Leukemia-LymphomaNCT03384654 · 47 enrolled · United States, Belgium, France and more
  7. Aug 17, 2018Phase 3 study in Multiple MyelomaNCT03652064 · 395 enrolled · United States, Brazil, Canada and more
  8. Nov 29, 2018Phase 4 study in Multiple MyelomaNCT03768960 · 150 enrolled · India
  9. Apr 2, 2019Phase 3 study in Multiple MyelomaNCT03901963 · 200 enrolled · United States, Canada
  10. Oct 8, 2019Phase 1 study in Multiple MyelomaNCT04121260 · 21 enrolled · China
  11. Nov 27, 2019Phase 3 study in Multiple MyelomaNCT04181827 · 419 enrolled · United States, Australia, Belgium and more
  12. Feb 11, 2022Phase 2 study in AmyloidosisNCT05250973 · 151 enrolled · United States, Canada, China and more
  13. Jun 24, 2022Phase 3 study in Multiple MyelomaNCT05438043 · 214 enrolled · United States, Belgium, Brazil and more
  14. Aug 27, 2024Phase 2 study in Multiple MyelomaNCT06577025 · 43 enrolled · United States, Australia, Brazil and more

Ahead

  1. Jan 31, 2029Primary completion: phase 3 study in Multiple MyelomaNCT05438043
  2. Sep 2, 2030Primary completion: phase 2 study in Multiple MyelomaNCT06577025

TargetBeta

CD38 →read by rule
“A human immunoglobulin G1-kappa (IgG1k) monoclonal antibody directed against the cell surface glycoprotein CD38, with immunomodulating and antineoplastic activities”NCIt, by rule
“Lymphocyte differentiation antigen CD38 inhibitor”ChEMBL 37, by rule

Other programs on CD38

ProgramCompanyFurthest phaseStudies
isatuximabruleSanofiphase 323
felzartamabruleBiogenphase 315
mezagitamabruleTakedaphase 311
lumrotatugruleKeymed Biosciencesphase 310
Anti-CD38 Monoclonal Antibody SCTC21CruleSinocelltech Groupphase 35
sanritatugruleHangzhou Sumgen Biotechphase 35
CID-103ruleCASI Pharmaceuticalsphase 23
Anti-BCMA/CD38/CD3 Trispecific Antibody ABBV-2001AbbViephase 22
Anti-CD38 Monoclonal AntibodyruleChongqing Genrix Biopharmaceuticalphase 21
Anti-CD38 Antibody-drug Conjugate ABBV-438AbbViephase 11

Studies

All 28 Johnson & Johnson leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06577025Multiple Myeloma · United States, Australia, Brazil and more2Active, not recruitingSep 2, 203043
NCT05438043Multiple Myeloma · United States, Belgium, Brazil and more3Active, not recruitingJan 31, 2029214
NCT05250973Amyloidosis · United States, Canada, China and more2Active, not recruitingFeb 4, 2026151
NCT04181827Multiple Myeloma · United States, Australia, Belgium and more3Active, not recruitingMay 1, 2024419
NCT04121260Multiple Myeloma · China1CompletedApr 27, 202121
NCT03901963Multiple Myeloma · United States, Canada3CompletedApr 4, 2024200
NCT03768960Multiple Myeloma · India4CompletedJul 16, 2022150
NCT03652064Multiple Myeloma · United States, Brazil, Canada and more3CompletedMay 7, 2024395
NCT03384654Precursor Cell Lymphoblastic Leukemia-Lymphoma · United States, Belgium, France and more2CompletedSep 22, 202247
NCT03277105Multiple Myeloma · United States, Australia, Brazil and more3CompletedJun 27, 2019522
NCT03234972Multiple Myeloma · China, Taiwan3CompletedOct 7, 2019213
NCT03217812Multiple Myeloma · China, Hong Kong, Korea, Republic of and more3CompletedJul 2, 2020220
NCT03201965Amyloidosis · United States, Australia, Belgium and more3CompletedFeb 14, 2020416
NCT03011034Myelodysplastic Syndromes · United States, Belgium, Italy and more2CompletedJan 23, 201934
NCT02951819Multiple Myeloma · United States2CompletedMar 8, 2018101
NCT02927925Lymphoma · China, Hong Kong, Korea, Republic of and more2CompletedJan 2, 202032
NCT02918331Multiple Myeloma · Japan1CompletedOct 20177
NCT02852837Multiple Myeloma · China1CompletedDec 13, 201950
NCT02497378Multiple Myeloma · Japan1CompletedMar 6, 20188
NCT02413489Lymphoma, Mantle-Cell · United States, Australia, Belgium and more2TerminatedJun 1, 201736
NCT02316106Multiple Myeloma · United States, Australia, Canada and more2CompletedJun 2, 2023123
NCT02252172Multiple Myeloma · United States, Australia, Austria and more3CompletedSep 24, 2018737
NCT02195479Multiple Myeloma · United States, Argentina, Australia and more3CompletedNov 21, 2017706
NCT02136134Multiple Myeloma · United States, Australia, Brazil and more3CompletedJan 11, 2016498
NCT02116569Multiple Myeloma · Japan1CompletedSep 20159
NCT02076009Multiple Myeloma · United States, Australia, Belgium and more3CompletedMar 7, 2016569
NCT01985126Multiple Myeloma · United States, Canada, Spain2CompletedJan 9, 2015124
NCT00574288Multiple Myeloma · United States, Denmark, Netherlands and more2CompletedJan 9, 2015104

How it is read

Names in the registry

  • “Daratumumab”, 32 entries
  • “daratumumab”, 3 entries
  • “Daratumumab SC”, 3 entries
  • “Daratumumab IV”, 2 entries
  • “CT-P44(Daratumumab)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.